No Data
Does PharmaResources (Shanghai) (SZSE:301230) Have A Healthy Balance Sheet?
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Hongbo Pharmaceutical (301230.SZ): plans to participate in the establishment of the partnership Lichen Yanhe.
On March 10, Gelonghui reported that Hongbo Biomedical (301230.SZ) announced that to meet the company's Global Strategy needs, it has signed a partnership agreement with Shanghai Liyuan Enterprise Management Partnership (Limited Partnership) and Shanghai Licheng Yuanding Private Investment Fund Partnership (Limited Partnership) to jointly establish the Shanghai Licheng Yanhe Enterprise Management Partnership (Limited Partnership) (referred to as "Licheng Yanhe"). The company contributes 7.3 million yuan in its own funds, accounting for 28.08% of the contribution ratio. This external investment focuses on early investment in Biomedical.
CSC: The potential of AI in pharmaceuticals is being released and is expected to reshape the future landscape of medicine.
AI is expected to reshape the model of drug discovery and bring subtle yet continuous cost reduction and efficiency improvement to the pharmaceutical Industry, driving the rapid growth of AI pharmaceutical pipelines and markets, and being Bullish on the long-term development potential and prospects of the AI pharmaceutical Industry.
Hongbo Pharmaceutical (301230.SZ): The company has not established a Business cooperation relationship with DeepSeek.
On February 21, Galonhui reported that Hongbo Pharmaceutical (301230.SZ) stated on the investor interaction platform that the company has not established a Business partnership with DeepSeek.
China Merchants: The blue ocean of AI in pharmaceuticals, with AI assisting the entire process of new drug development.
Previously, the application of AI technology in the drug development process mainly focused on the drug discovery stage. With the application of large model technologies like Deepseek, the value of AI in the clinical stage will gradually become evident.
Declining Stock and Decent Financials: Is The Market Wrong About PharmaResources (Shanghai) Co., Ltd. (SZSE:301230)?